Latest immunotherapies Stories
SAN DIEGO, Dec. 15, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc.
SCIB1 continues to generate highly encouraging survival data; Modi-1 vaccine on track for 2016 entry into clinic NOTTINGHAM, England, December 10, 2014 /PRNewswire/ --
Invetech to supply automated production systems for commercialization of patient-specific immunotherapies based on Argos' proprietary Arcelis® technology platform. SAN DIEGO and DURHAM,
PhosImmune and PureMHC Working Together On Immunotherapies for Cancer CHARLOTTESVILLE, Va. and AUSTIN, Texas, Oct. 22, 2014 /PRNewswire/ -- PhosImmune Inc.
New Executive Brings Experience from Merck, Boehringer Ingelheim, and Proctor & Gamble PLYMOUTH MEETING, Pa., Sept. 30, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc.
TUEBINGEN, Germany, July 16, 2014 /PRNewswire/ -- Funds will be used to complete phase 3 study with IMA901 and to invest in the expansion of immatics' Human Immunopeptidome
SEOUL, South Korea, BUSAN, South Korea and SAN FRANCISCO, July 10, 2014 /PRNewswire/ -- SillaJen, Inc., a privately-held biotherapeutics company focused on the development of
Immune Checkpoint Inhibitors Will Hold an Impressive 85 Percent Market Share, According to Findings from Decision Resources Group BURLINGTON, Mass., June 30, 2014 /PRNewswire/ -- Decision Resources
LONDON, June 10, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
IPSWICH, Mass., April 28, 2014 /PRNewswire/ -- New England Biolabs (NEB(®)) announces that it has been awarded a $250,000 grant from the Massachusetts Life Sciences Center (MLSC) to
- A person in a secondary role, specifically the second most important character (after the protagonist).